Bayesian trial of adalimumab versus secukinumab for children with juvenile idiopathic arthritis associated uveitis or chronic anterior uveitis

URN to cite this document:: urn:nbn:de:bvb:355-epub-777137
DOI to cite this document:: 10.5283/epub.77713

Ramanan, Athimalaipet V. ; Dick, Andrew D. ; Jaki, Thomas

; Caruso, Gianmarco ; Robertson, David S. ; Jones, Ashley P. ; Hardwick, Ben ; Drake, Sian ; Balasubramaniam, Balini ; Ciurtin, Coziana ; Foeldvari, Ivan ; Kreps, Elke O. ; Leahy, Alice ; May, Kristina ; Quartier, Pierre ; Robert, Matthieu P. ; Simonini, Gabriele ; Guly, Catherine ; Beresford, Michael W.

License: Creative Commons Attribution 4.0
PDF - Published Version
(1MB)

Date of publication of this fulltext: 18 Sep 2025 10:07

Alternative links to fulltext:DOI Publisher

Details

Preview

Export bibliographical data

Abstract

Background: Juvenile idiopathic arthritis (JIA)-associated uveitis and chronic anterior uveitis in children may result in permanent sight loss. Currently, the only licensed and approved treatment for JIA-uveitis is adalimumab. However, even in patients where adalimumab may be initially effective, therapeutic response may subside for example, due to neutralising drug antibodies. Further treatment ...